Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 1,695 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asthma (Diagnosis) Clear all
Completed Phase 3 Interventional Results available

Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

NCT02918071
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Northridge, California • Riverside, California • Westminster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)

NCT03528577
View directory record Official record
Conditions
Asthma
Interventions
Zero-dose, 90 mcg of PROAIR® HFA, 180 mcg of 90 mcg of PROAIR® HFA, 90 mcg of albuterol sulfate inhalation aerosol
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 2 Interventional

Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma

NCT04946318
View directory record Official record
Conditions
Asthma
Interventions
CSJ117, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Bakersfield, California • Huntington Beach, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age

NCT01995175
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Nasal swab sampling, Blood sampling, Diary cards
Procedure · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 6 Years
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2021
U.S. locations
9
States / cities
Oakland, California • Sacramento, California • Santa Clara, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 13, 2026, 11:37 PM EDT
Withdrawn Phase 2 Interventional

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

NCT01304628
View directory record Official record
Conditions
Asthma
Interventions
PL-3994
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 13, 2026, 11:37 PM EDT
Completed No phase listed Observational Results available

Progression of Airway Obstruction in Childhood Asthma

NCT00873873
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
16 Years to 40 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional

Nutrition for Asthmatics with Obesity

NCT05222451
View directory record Official record
Conditions
Asthma, Obesity
Interventions
DGA Diet, MCT Diet, KETO Diet
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 13, 2026, 11:37 PM EDT
Recruiting No phase listed Observational

Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma

NCT02241265
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

NCT02443298
View directory record Official record
Conditions
Asthma
Interventions
placebo, risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
20
States / cities
Costa Mesa, California • Mountain View, California • Centennial, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional

The Provider and Organization in Asthma Guidelines

NCT00345514
View directory record Official record
Conditions
Asthma
Interventions
Behavioral Intervention Arm, Organizational Interventions Arm
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 1 Interventional Results available

A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma

NCT03421730
View directory record Official record
Conditions
Wheezing, Reactive Airway Disease, Mild Asthma
Interventions
VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System, 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Combination Product
Lead sponsor
Vectura Limited
Industry
Eligibility
4 Years to 8 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Colorado Springs, Colorado • Raleigh, North Carolina • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Tolerability Study of Arformoterol Tartrate Inhalation Solution in Pediatric Subjects

NCT00583947
View directory record Official record
Conditions
Asthma
Interventions
arformoterol, levalbuterol
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
2 Years to 11 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
14
States / cities
Beverly Hills, California • Orange, California • Savannah, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated Phase 4 Interventional

Childhood Asthma Research and Education (CARE) Network Trial - Montelukast or Azithromycin for Reduction of Inhaled Corticosteroids in Childhood Asthma (MARS)

NCT00471809
View directory record Official record
Conditions
Asthma
Interventions
Budesonide + Salmeterol + Azithromycin, Budesonide + Salmeterol + Montelukast, Budesonide + Salmeterol + Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
6 Years to 17 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aligning With Schools To Help Manage Asthma (Project ASTHMA)

NCT03032744
View directory record Official record
Conditions
Asthma
Interventions
Asthma Assessment & Management, Asthma Education, Controller medication at school
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
4 Years to 14 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Completed No phase listed Observational

Evaluation of ST2 and IL-33 in Patients Presenting to the Emergency Department With Trouble Breathing

NCT00707811
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma, Pulmonary Embolism, Pneumonia, Congestive Heart Failure
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Oct 13, 2026, 11:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of the Medentum Diagnostik Platform for Pediatric ENT Conditions and Asthma

NCT07500532
View directory record Official record
Conditions
Acute Otitis Media (AOM), Strep Pharyngitis, Asthma Exacerbation, Pediatric Asthma
Interventions
Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of AOM and strep pharyngitis, Diagnostik home-based platform: multisensor device, software application, and artificial-intelligence algorithms that predict diagnosis of wheeze/asthma exacerbation, Routine Asthma Management (in-person and telehealth visits)- Control Group, Routine ENT Management (in-person and telehealth visits)- Control Group
Device · Other
Lead sponsor
Medentum Innovations
Industry
Eligibility
3 Years to 17 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Tuscon, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 13, 2026, 11:37 PM EDT
Terminated No phase listed Observational

A Methodology Study To Look At Genes In Lung Cells And Tissue From Asthmatic Patients

NCT00331292
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional Results available

CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)

NCT00675584
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, Placebo Budesonide
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 53 Months
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Levalbuterol Versus Racemic Albuterol in Asthma

NCT00667407
View directory record Official record
Conditions
Asthma
Interventions
Levalbuterol 1.25 mg, Racemic Albuterol Sulfate
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
28
States / cities
Hoover, Alabama • Montgomery, Alabama • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma

NCT00180011
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
DiMango, Emily, M.D.
Individual
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 13, 2026, 11:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

NCT00814281
View directory record Official record
Conditions
Airway Inflammation
Interventions
placebo, Montelukast
Other · Drug
Lead sponsor
Marywood University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2009 · Synced Oct 13, 2026, 11:37 PM EDT